ABSTRACT
INTRODUCTION
. The term ''fibrositis'' appeared in the early 1900s to describe the condition, with inflammation of the connective tissues assumed to be the underlying pathophysiology [5] . The assumption persisted until systematic scientific studies began to appear in the literature in the 1970s, when an underlying inflammation was ruled out and a more neutral term fibromyalgia proposed [6, 7] .
Several criteria, based on common clinical presentations, were delineated in the 1970s and 1980s (e.g., [8, 9] ), stimulating a proliferation of research in the field.
However, these criteria were rarely applied consistently and the lack of standardization made integration of the study findings very difficult.
Diagnostic Criteria
In the late 1980s, a multicenter study was conducted with the intention of developing empirically derived classification criteria for FMS [1] . The study included approximately 300 patients with FMS and 285 controls with other (non-FMS) painful conditions.
Comparison of a number of FMS-related variables revealed two criteria with good sensitivity and specificity that can differentiate between the two groups. These criteria, generally referred as the American College of Rheumatology (ACR) criteria, consist of (1) a history of widespread pain of 3 months or longer duration and (2) presence of pain responses at least 11 of 18 designated tender points (TPs) [1] . Since publication in 1990, the ACR criteria have become a standard in FMS research. They have been used by the vast majority of published reports on FMS to date, creating some cohesiveness in the literature. However, the ACR criteria are not free from criticisms.
One or more TPs represents any clinical significance or relevance to FMS. Altogether, the validity of the TP count criterion is yet to be determined.
Another concern regarding the ACR criteria is the lack of consideration of common symptoms and dysfunctions. Chronic fatigue and sleep problems are ubiquitous in FMS patients; however, they were not included in the ACR criteria because they are also commonly experienced by other patients with chronic pain and thus yielded unsatisfactory discriminability. However, those symptoms are common enough to be characteristics of the disorder yet not a part of the diagnostic criteria; this is a stark contrast with other syndromes such as depression where a diagnosis relies on the presence of multiple common clinical phenomena.
However, there is no question that the ACR classification criteria provided much-needed consistency in defining fibromyalgia for research studies. Unfortunately, the clinical utility of the ACR criteria is quite limited [15] and the concordance between the ACR criteria and clinical diagnosis is rather poor [16] . In order to address these concerns, new diagnostic criteria for FMS were proposed recently, based on data from another multicenter study [17] .
The new criteria involve the assessment by clinicians of common symptoms such as fatigue, unrefreshed wakening and cognitive symptoms. The authors of the 2010 ACR criteria specifically note that these new classification criteria are not intended to replace the 1990 ACR classification criteria, but to be used as a clinical tool in primary care and specialized clinics. Eliminating the need to perform a physical examination for the new criteria would facilitate the use of the standardized measure to diagnose fibromyalgia in clinical settings. Furthermore, for certain research studies, such as a large epidemiological project where conducting TP examination is not feasible, the new criteria will provide a degree of standardization in the study samples. The details of the ACR criteria are listed in Table 1 .
Pathophysiology
The etiology of FMS is unknown. However, accumulated evidence over the past 40 years suggests that several factors potentially underlie the disorder. Although the focus of this paper is primarily on the management of FMS, we will briefly review the literature, including the role of central pain modulation processes, muscle abnormality, neuroendocrine regulation, and sleep.
Central Pain Modulation
Research has consistently shown that FMS is associated with increased pain sensitivity that suggests dysregulation of the pain modulation process at the central level. [43] , and they show a significant increase in gene expression of adrenergic molecular receptors in response to exercise, as well as at rest, as compared to healthy controls [44, 45] , implicating a genetic vulnerability in at least some FMS patients.
Muscular Abnormalities and Peripheral Pain Modulation
Although an early study found abnormal biopsy results in the painful muscles in FMS patients [46] , the investigation of local muscle tissue has yielded conflicting results. In general, evidence supporting the microscopic evidence of definitive pathology in the muscle tissues in FMS is scarce [47] . However, a peripheral abnormality, albeit limited, may contribute to FMS pathophysiology. For example, affected (i.e., painful) muscles of FMS patients show hypoxia [48] . Some studies using P-31 magnetic resonance spectroscopy [49, 50] have also shown reduced levels of adenosine triphosphate and phosphocreatine in FMS, suggesting that these metabolic abnormalities may contribute to muscle weakness and fatigability in FMS. Decreased muscle blood flow, as compared to healthy individuals, has also been shown [51] . Problems with muscular vasoconstriction (e.g., Raynaud's syndrome) are common in FMS [52] . These results suggest that peripheral ischemia may contribute to muscle pain. Furthermore, a significantly greater number of active myofascial trigger points in the trapezius muscles are found in FMS patients relative to healthy people [53] . The number of active trigger points seems to be related to diffuse mechanical hyperalgesia in FMS [54] , suggesting that peripheral noxious inputs play a critical role; peripheral abnormality may create a biochemical environment that contributes to local sensitization, leading to central pain sensitivity [55] .
TREATMENT OF FMS
Over the past four decades, a large variety of modalities have been tested for treating FMS. Overall, no single modality has been found to be universally effective for all FMS patients, or all FMS symptoms in an individual patient. Below, we will review commonly used FMS treatments as well as some treatments that have attracted much public attention. A comparative evaluation of pregabalin, milnacipran and duloxetine [72] showed similar efficacy of the three drugs with regard to pain reduction. However, there were some differences in the secondary outcome measures and adverse effects, suggesting that these differences may guide a clinical decision as to which of these agents to use for a particular patient.
Pharmacologic Options

FDA-Approved Agents
One of the concerns with these trials is the relatively high placebo response rates. For the purpose of illustration, Fig. 1 and is considered one of the most popular party drugs. It also causes amnesia and increased passivity that has been used to aid criminal activity (e.g., ''date rape''). However, in general, the problems related to illicit GHB have been declining significantly since the turn of the century; nevertheless the risk associated with the illicit GHB seems to greatly exceed that of legally prescribed sodium oxybate [75] .
Abuse and misuse complications of sodium oxybate are relatively rare according to the post marketing data [75, 76] .
Its ability to restore slow wave sleep (SWS) [77] has led to a series of trials to evaluate the efficacy of sodium oxybate for treating FMS and an application to the FDA. An early small, crossover RCT [78] showed that sodium oxybate 6 g a day at bedtime for 4 weeks significantly improved pain, fatigue, and sleep (restored SWS) as compared to placebo. More recently, multicenter studies [79] [80] [81] have shown that sodium oxybate 4.5-6 g per night significantly improved clinical pain and Russell et al. [80] FMS-related symptoms relative to placebo. [82] ) for sodium oxybate 4.5 and 6 g and placebo.
The outcomes for the two sodium oxybate doses do not seem to differ. All studies found relatively high placebo response rates. The dropout rates were also relatively high due to adverse effects, particularly for the higher dose group (see Table 3 [79-81] for treatment completion rates for each study). Another concern regarding the use of sodium oxybate is its very short elimination half-life of approximately 30 min to 1 h [83] . For this reason, the dose was divided into two half doses, and the patients were required take a half dose at bedtime and wake up 2.5-4 h after bedtime to take another half dose. Interrupting the sleep of patients with existing sleep disturbance seems rather counterproductive [84] . Nevertheless, a polysomnographic study [85] demonstrated that sodium oxybate 6 g per night in a divided dose led to a significant improvement in the sleep measures in FMS, including total sleep time, waking after sleep onset, slow and wave sleep time.
The application for the FDA approval of sodium oxybate for treating FMS was denied in 2010. The advisory committee [86] concluded that the efficacy data, although promising, do not show superior results to currently approved medications. They also expressed significant concern with the safety issues of the drug, with a potential for abuse and misuse with serious consequences. They felt that adequate safety measures were not available at the time.
Tricyclics and Other Antidepressants
A meta-analysis [87] demonstrates that these agents help to reduce pain, fatigue, and sleep disturbance in FMS. However, there seems to be a large individual variation in the treatment response, and it has been estimated [88] that approximately 30% of patients may benefit from tricyclics. The introduction of selective serotonin reuptake inhibitors (SSRIs) was received with much enthusiasm as they were considered to be a safer alternative to TCAs and could regulate serotonin reuptake. However, the results from RCTs were marginal for improving pain, sleep and mood in FMS patients [89, 90] , even with a flexible dose [91] .
Analgesics Corticosteroids were one of the first classes of medications to be tested for FMS; however, a double-blind RCT evaluating prednisone showed no clinical benefit [92] .
Common over-the-counter analgesics such as non-steroidal anti-inflammatory drugs, although widely used by FMS patients, also do not appear to have any appreciable benefit [93] .
The use of opioid analgesics in FMS does not seem to be very common [94] , and they are generally not recommended for treating FMS,
due to the lack of demonstrated efficacy [95] . Tramadol with the combined actions of weak opioid and norepinephrine and serotonin reuptake inhibitor (SNRI) effects has shown An early retrospective chart review study [100] of 20 patients with non-cancer chronic pain found some improvement in pain and sleep, suggesting a potential benefit for chronic pain patients in general as an analgesic. In the first double-blind RCT [101] , 40 FMS patients received either placebo or nabilone (titrated to 1 mg twice daily) for 4 weeks. The nabilone group showed significant decrease in pain and FIQ score relative to the placebo group at the post-treatment assessment, although the benefit seemed to disappear at the 8-week follow-up. The nabilone group had a greater dropout rate (25%) versus the placebo group (10%) and reported more drowsiness (50%), dry mouth (30%) and vertigo (27%). Ware et al. [102] compared nabilone to amitriptyline in a crossover trial where patients received a 2-week trial of each drug with a 2-week washout in between. Adverse effects (dizziness, nausea, dry mouth, drowsiness) were more prominent with nabilone. The two drugs showed a comparative decrease in sleep disturbance, although it is not clear whether there was a between-group difference in the degree of benefit. The groups did not differ with regard to the other FMSrelated symptoms, although it was not clear whether they showed any improvement with either treatment. Unfortunately, recruitment was difficult, with approximately half of patients who were approached declining to participate, making it difficult to ascertain the representability of the study sample. A systematic review of cannabinoids for treating non-cancer chronic pain [103] suggests that they are safe and may have some modest benefit for FMS, although the results are very preliminary at this point. The issues of longterm benefit and adverse effects need to be thoroughly investigated. Mindfulness-based stress reduction (MBSR) is an increasingly popular approach to treat various chronic illnesses. For FMS, an early study [110] showed some promising reduction in pain and symptoms with MBSR training relative to a control group. However, a subsequent 3-arm study comparing MBSR training to both active control (supportive group with relaxation training) and wait list group failed to show any benefit [111] .
Non-Pharmacologic Options
Complementary and alternative (CAM) approaches are very popular with FMS patients. Unfortunately, many of the trials are not well-controlled or included small numbers of patients. Because of the methodologic concerns, the level of clinical benefit of CAM therapies for FMS cannot be determined from the current literature [112] .
One of the most widely accepted behavioral therapy modalities is cognitive-behavioral therapy (CBT). Clinical trials testing CBT alone, however, tend to be small with various methodologic problems, making it difficult to interpret its efficacy. In general, CBT monotherapy is effective in improving the target variables (e.g., maladaptive cognition, mood, quality of life; QOL) [113] [114] [115] although the effects on the primary FMS symptoms may be limited. The efficacy seems to improve when CBT is included as a part of a multidisciplinary treatment program (see below).
Multidisciplinary Treatment
Given the complex, multifactorial nature of FMS, it is reasonable to assume that multimodal therapy targeting multiple factors may work well. However, systematic evaluation of studies evaluating multidisciplinary therapy for FMS is difficult because of the wide variability in the parameters of the treatment. Unfortunately, the lack of methodological vigor is not uncommon, reflecting the difficulty of conducting costly, logistically demanding trials using multimodal approaches.
Although there are some other variations, a typical trial testing a multidisciplinary approach includes education, exercise and psychological (typically cognitive behavioral) therapy.
Programs aimed at acquisition of coping and pain management skills seem to provide better results than those that mostly aim to provide information/education [109] . A systematic review [116] points to the methodological
weakness, yet provides some evidence of the effectiveness of the approach for various chronic pain conditions including FMS. The effectiveness seems to last beyond the therapy; reduction in pain and other symptoms was observed 12 months later [117] . A recent recommendation [118] by FMS experts strongly emphasizes the importance of educating patients, establishing working goals, and applying multimodal therapy approaches consisting of education, medications, exercise and CBT. There has only been one published study thus far that specifically tested the combination of CBT with medication [119] . In this trial, patients were randomized to a combination of CBT and milnacipran, drug monotherapy or CBT alone. The results suggest that the combination approach and CBT monotherapy were equally beneficial in reducing symptoms, i.e., milnacipran added very little to the clinical benefit of CBT. 
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